Get the Daily Brief
Latest Biotech News
Complement gene variants shape pancreatic cancer susceptibility and outcomes
A Nature Communications study mapped how genetic variation in complement system genes impacts pancreatic cancer risk and prognosis (5824da7fa241d818). The analysis integrated genomic datasets to...
Eli Lilly unveils RXFP1 agonists — broad therapeutic targets
Eli Lilly disclosed a new series of RXFP1 (relaxin receptor 1) agonists in a recent patent disclosure, positioning the compounds across indications that include pulmonary hypertension, chronic...
Boehringer Ingelheim files cGAS inhibitors — autoimmune and fibrotic stakes
Boehringer Ingelheim disclosed novel cyclic GMP‑AMP synthase (cGAS) inhibitors designed to blunt innate immune sensing in disorders driven by aberrant interferon signalling. The company’s filing...
Kymera patents STAT6 inhibitors — inflammation to oncology opportunity
Kymera Therapeutics disclosed novel STAT6 inhibitors in a recent patent publication, broadening its targeted‑protein degradation and small‑molecule portfolio into the STAT transcription factor...
Telix faces shareholder class action notice — litigation risk for radiopharma
A U.S. law firm issued a notice seeking Telix Pharmaceuticals shareholders potentially harmed during a defined class period, prompting investor scrutiny of Telix’s commercial and disclosure...
Kedrion wins EU orphan tag for aceruloplasminemia — rare‑disease push
Kedrion SpA secured European orphan drug designation for its investigational plasma‑derived therapy for congenital aceruloplasminemia, the company announced. The EMA’s orphan tag applies to a...
Vivace TEAD inhibitor shows preclinical hits in NF2 models — meningioma angle
Vivace Therapeutics reported preclinical efficacy for VT‑3989, a TEAD inhibitor showing activity in NF2‑deficient meningioma models and other aggressive tumor types. Company data presented include...
M‑3554 ADC shows anti‑tumor activity — GD2 target in sarcoma and neuroblastoma
An antibody‑drug conjugate, M‑3554, demonstrated strong antitumor activity in neuroblastoma xenograft models and shows engineered features intended to reduce GD2‑associated pain, according to...
mRNA engineering bolsters allogeneic MSC therapy — DC‑25 emerges
Researchers reported mRNA engineering of mesenchymal stem cells (MSCs) to create DC‑25, an allogeneic cell therapy designed to enhance immunomodulatory function and overcome limitations of...
MAP‑X maps malaria protein networks — dynamic interactome across lifecycle
Scientists introduced MAP‑X, a technique that charts protein complex dynamics across Plasmodium falciparum’s intraerythrocytic developmental cycle, revealing stage‑specific interactions that drive...
Apalutamide vs enzalutamide: survival debate — comparative letters and analyses
Recent correspondence and analyses revisited survival outcomes comparing apalutamide and enzalutamide in metastatic castration‑sensitive prostate cancer (mCSPC). A primary report examined...
FDA proposes plausible-mechanism pathway: expedited route for bespoke rare therapies
US regulators and academics published a proposed “plausible mechanism” pathway to accelerate access to bespoke medicines for ultra-rare conditions. Vinay Prasad and Martin Makary (FDA authors)...
Off-the-shelf mRNA vaccines: new immunotherapy approach for liver cancer
Researchers reported development of off‑the‑shelf mRNA vaccines targeting hepatocellular carcinoma (HCC) that elicit tumor-directed immune responses in preclinical models. The work outlines...
Bird flu tolerates fever: PB1 gene enables high-temperature replication
Researchers identified the viral PB1 gene as the determinant allowing avian influenza strains to replicate at fever-range temperatures that suppress human-origin viruses. Mouse experiments...
mRNA engineering boosts allogeneic stem cells: DC‑25 shows immunotherapy promise
Scientists engineered mesenchymal stromal cells (MSCs) with synthetic mRNA to produce an allogeneic cell therapy dubbed DC‑25 that enhances immune-modulatory signals and resists host rejection....
Drugmakers expand small-molecule arsenals – Kymera’s STAT6 and Schrödinger’s mutant EGFR
Two patent disclosures signaled fresh small-molecule efforts in oncology and immune disorders: Kymera filed STAT6 inhibitors intended for cancer and inflammatory diseases, while Schrödinger...
Boehringer discovers cGAS inhibitors: new candidates for interferon-driven diseases
Boehringer Ingelheim reported discovery of small-molecule cGAS inhibitors with potential applications across autoinflammatory interferonopathies, idiopathic pulmonary fibrosis,...
Targeting cell-death pathways: Cathepsin L and sibiriline offer dual benefits for cancer and degeneration
Two independent preclinical advances map therapeutic routes through regulated cell-death pathways. A Nature Communications study identified Cathepsin L as a dual target that suppresses tumor...
Kedrion wins EU orphan designation for aceruloplasminemia: plasma-derived therapy advances
Kedrion SpA announced European Medicines Agency orphan-drug designation for its investigational plasma-derived therapy to treat congenital aceruloplasminemia. The designation aims to facilitate...
Single 2‑ml mirikizumab injection bioequivalent to two 1‑ml doses: administration simplified
A clinical pharmacology study led by Otani, Payne and Loftus showed a single 2‑ml subcutaneous injection of mirikizumab is bioequivalent to two separate 1‑ml injections in healthy volunteers. The...